The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...
Genentech, a member of the Roche Group (SIX ... Including a Potential Sale Vista Outdoor Inc. ("Vista Outdoor", the "Company") today issued the following statement from the Company's Chairman of the ...
Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...
Mr. Mullins added, “I am thrilled to join Tempest at such an exciting time as the team prepares to advance amezalpat into a pivotal study. Amezalpat has demonstrated very strong results in the ...